Poster, Podium & Video Sessions
Presentation Authors: Bethany Desroches*, Xinyi Wang, Pu Duann, Meredith Rae, Swathi Balaji, Sundeep Keswani, Houston, TX
Introduction: Clinical unilateral ureteral obstruction (UUO) results from pathologies like ureteral calculi, malignancy, trauma, and periureteral fibrosis. UUO requires prompt surgical intervention to prevent progressive inflammation, fibrosis, and kidney function impairment. Novel therapies are needed to recover renal function and architecture after obstruction. Previous reports show the anti-inflammatory cytokine interleukin-10 (IL-10) attenuates fibrosis in a murine model. We and others have shown IL-10 regulates angiogenesis and endothelial progenitor recruitment during dermal and ischemic cardiac tissue repair. We hypothesize that IL-10 can promote angiogenesis and prevent microvascular rarefaction in a murine UUO model.
Methods: 8 week-old C57BL/6J (WT) mice and IL-10 null male mice were injected with lenti-IL-10/lenti-GFP (1x1010 IU) under the renal capsule. Three days after injection, UUO was performed. 14 days after UUO, UUO/sham kidneys and serum were collected for RNA, ELISA and immunohistochemical analysis of VEGF and TGFβ isoforms. Primary fibroblasts were isolated from 8-10 week-old male WT mice. IL-10 (50 ng/ml or 200 ng/ml) was added to cultures. VEGF and TGFβ-1 gene expressions were assessed by qPCR at 1, 2, 3 and 6h. Levels of TGFβ-1 and TGFβ-3 were determined at 48h by ELISA. Data presented as mean±SD, n=3/treatment group. P value by ANOVA.
Results: IL-10 treatment, in vitro, increased VEGF expression (related to physiologic angiogenesis) and altered the expression of TGFβ isoforms (related to pathologic fibrosis). Lenti-Il10 treatment in mice with UUO reduced fibrotic changes between tubules (45±7%, p<0.05) and attenuated tubular dilatation (p<0.05, n=30/group). CD31, an endothelium marker essential to preserving tubular integrity, was normally expressed in healthy kidney parenchyma and decreased after UUO. IL-10 null mice showed a lower basal level of CD31 than WT mice. In both WT and IL-10 null mice, IL-10 treatment preserved CD31, suggesting a role in rescuing integral peritubular capillaries.
Conclusions: Ureteral obstruction can cause remodeled renal architecture and decrease in renal function. Our results in a murine UUO model show that IL-10 can effectively promote angiogenesis in vitro and prevent microvascular rarefaction in vivo. Mice treated with IL-10 show decreased fibrotic change and increased markers for tubular integrity. These results from the in vivo studies of UUO, and the in vitro studies of IL-10&[prime]s influence in angiogenesis and fibrosis of the kidney, may lead to novel treatments for the sequelae of urinary tract obstruction.
Source Of Funding: NIGMS R01 GM111808
Baylor College of Medicine
Bethany Desroches, ScB, ScM, MD is currently a PGY3 at the Scott Department of Urology at Baylor College of Medicine in Houston, Texas. Born and raised in Brooklyn, NY, she attended Brown University where she completed her BS with Honors in Cellular and Molecular Biology, and her MS in Artificial Organs, Biomaterial and Cellular Technologies. Her basic science research with Dr. Ulrike Mende at the Cardiovascular Research Center at Rhode Island Hospital focused on functional scaffold-free 3D cardiac microtissues. She returned to Brooklyn to complete her MD at SUNY Downstate College of Medicine. She is now in her third year of a five year urology residency at Baylor College of Medicine, and is enthusiastically involved in Dr. Sundeep Keswani and Dr. Swathi Balaji's basic science research at the Laboratory for Regenerative Tissue Repair at Texas Children's Hospital. She looks forward to a career in academic urology, and hopes to pursue fellowship in Minimally Invasive (Laparoscopic and Robotic) Surgery.
Friday, May 12
4:40 PM – 4:50 PM